15 reports of this reaction
1.6% of all NEOSTIGMINE METHYLSULFATE reports
#11 most reported adverse reaction
GENERALISED TONIC CLONIC SEIZURE is the #11 most commonly reported adverse reaction for NEOSTIGMINE METHYLSULFATE, manufactured by Exela Pharma Sciences, LLC. There are 15 FDA adverse event reports linking NEOSTIGMINE METHYLSULFATE to GENERALISED TONIC CLONIC SEIZURE. This represents approximately 1.6% of all 959 adverse event reports for this drug.
Patients taking NEOSTIGMINE METHYLSULFATE who experience generalised tonic clonic seizure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GENERALISED TONIC CLONIC SEIZURE is a less commonly reported adverse event for NEOSTIGMINE METHYLSULFATE, but still significant enough to appear in the safety profile.
In addition to generalised tonic clonic seizure, the following adverse reactions have been reported for NEOSTIGMINE METHYLSULFATE:
The following drugs have also been linked to generalised tonic clonic seizure in FDA adverse event reports:
GENERALISED TONIC CLONIC SEIZURE has been reported as an adverse event in 15 FDA reports for NEOSTIGMINE METHYLSULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GENERALISED TONIC CLONIC SEIZURE accounts for approximately 1.6% of all adverse event reports for NEOSTIGMINE METHYLSULFATE, making it a notable side effect.
If you experience generalised tonic clonic seizure while taking NEOSTIGMINE METHYLSULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.